Travere Therapeutics Inc (TVTX)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current TVTX market cap is 775.75M. The company's latest EPS is USD -1.4633 and P/E is -6.96.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 56.99M | 59.7M | -16.51M | 45.06M | 41.37M |
| Operating Income | -87.05M | -87.58M | -127.87M | -94.23M | -139.24M |
| Net Income | -86.33M | -85.63M | 150.74M | -90.17M | -136.06M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 193.34M | 198.32M | 227.49M | 212.02M | 145.24M |
| Operating Income | -122.36M | -176.16M | -161.77M | -266.57M | -388.14M |
| Net Income | -146.43M | -169.43M | -180.09M | -278.48M | -111.4M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 808.23M | 736.43M | 832.85M | 788.91M | 663.55M |
| Total Liabilities | 619.09M | 619.94M | 553.08M | 588.1M | 589.48M |
| Total Equity | 189.14M | 116.49M | 279.77M | 200.81M | 74.07M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 604.8M | 607.44M | 776.63M | 672.59M | 788.91M |
| Total Liabilities | 383.6M | 396.23M | 474.52M | 629.73M | 588.1M |
| Total Equity | 221.2M | 211.21M | 302.11M | 42.85M | 200.81M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -81.12M | -150.41M | -209.55M | -280.02M | -119.01M |
| Investing | -37.04M | -60.59M | 72.73M | 55.78M | 104.9M |
| Financing | 217M | 219.26M | 218.63M | 218.75M | -525k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -58.21M | -42.74M | -14.79M | -186.29M | -280.02M |
| Investing | 19.86M | -61.33M | -137.62M | -32.55M | 55.78M |
| Financing | -2.08M | 127.71M | 231.68M | 117.57M | 218.75M |
| Market Cap | 775.75M |
| Price to Earnings Ratio | -6.96 |
| Price to Sales Ratio | 5.34 |
| Price to Cash Ratio | 13.33 |
| Price to Book Ratio | 3.86 |
| Dividend Yield | - |
| Shares Outstanding | 76.13M |
| Average Volume (1 week) | 675.51k |
| Average Volume (1 Month) | 1.03M |
| 52 Week Change | -41.03% |
| 52 Week High | 17.5699 |
| 52 Week Low | 5.12 |
| Spread (Intraday) | 0.18 (1.77%) |
| Company Name | Travere Therapeutics Inc |
| Address |
16192 coastal hwy lewes, delaware 19958 |
| Website | https://travere.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
